Chronic Lymphocytic Leukemia (CLL)

Chronic lymphocytic leukemia (CLL) is the most common leukemia of adults and is traditionally considered incurable. The Center for Chronic Lymphocytic Leukemia at Dana-Farber Cancer Institute was established more than ten years ago and is one of only a few programs in the country dedicated to this B-cell malignancy. As such, the Center has unique expertise in caring for patients with CLL and serves as a central hub for CLL research.

Matthew Davids, MD, MMSc, Director, Clinical Research, Lymphoma Program, and his colleagues are working to characterize the underlying biology and genomics of CLL, while also leading the development of novel targeted and cellular therapies to treat the disease. In fact, Dr. Davids’ and his colleagues were instrumental in the clinical development of all six of the small-molecule targeted agents approved by the Food and Drug Administration (FDA) to treat CLL over the past decade, bringing hope to more patients and their families.

Dr. Davids is dedicated to pushing the boundaries of scientific discovery and translating the Center’s findings into new treatments for patients. This work is only possible with visionary philanthropic support.